董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrew Dreyfus | 男 | Director | 67 | 8.03万美元 | 2.46 | 2026-05-27 |
| Andrew Miller | 男 | Independent Director | 44 | 未披露 | 未持股 | 2026-05-27 |
| Christopher Nixon Cox | 男 | Director | 47 | 11.05万美元 | 73.93 | 2026-05-27 |
| Gwill York | 女 | Director | 69 | 8.82万美元 | 8.96 | 2026-05-27 |
| Amit Etkin | 男 | President, Chief Executive Officer and Chair of the Board | 50 | 218.85万美元 | 158.55 | 2026-05-27 |
| Husseini Manji | 男 | Director | 67 | 7.31万美元 | 1.94 | 2026-05-27 |
| Raymond Sanchez | 男 | Director | 65 | 8.49万美元 | 未持股 | 2026-05-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Amit Etkin | 男 | President, Chief Executive Officer and Chair of the Board | 50 | 218.85万美元 | 158.55 | 2026-05-27 |
| Nicholas Smith | 男 | Chief Financial Officer and Chief Business Officer | 38 | 154.16万美元 | 32.07 | 2026-05-27 |
董事简历
中英对照 | 中文 | 英文- Andrew Dreyfus
-
Andrew Dreyfus，他一直担任Alto Neuroscience， Inc.的董事会成员（2009年10月以来）。2005年8月至2022年12月，Dreyfus先生在马萨诸塞州蓝十字蓝盾（一家健康保险公司）担任越来越重要的职务，最近从2010年9月至2022年12月担任总裁兼首席执行官。他曾担任Ironwood pharmaceuticals， Inc.（制药公司）的董事会成员（2016年4月以来），并担任非营利组织的众多董事会和顾问委员会成员。他持有Connecticut College的英语学士学位。
Andrew Dreyfus,has served as a member of Alto Neuroscience, Inc. board of directors since October 2023. From August 2005 to December 2022, Mr. Dreyfus served in roles of increasing responsibility at Blue Cross Blue Shield of Massachusetts, a health insurance company, most recently serving as President and Chief Executive Officer from September 2010 to December 2022. Mr. Dreyfus has served as a member of the board of directors of Ironwood Pharmaceutics, Inc., a pharmaceutical company, since April 2016, and serves on numerous boards and advisory boards for non-profit organizations. Mr. Dreyfus received a B.A. in English from Connecticut College. - Andrew Dreyfus，他一直担任Alto Neuroscience， Inc.的董事会成员（2009年10月以来）。2005年8月至2022年12月，Dreyfus先生在马萨诸塞州蓝十字蓝盾（一家健康保险公司）担任越来越重要的职务，最近从2010年9月至2022年12月担任总裁兼首席执行官。他曾担任Ironwood pharmaceuticals， Inc.（制药公司）的董事会成员（2016年4月以来），并担任非营利组织的众多董事会和顾问委员会成员。他持有Connecticut College的英语学士学位。
- Andrew Dreyfus,has served as a member of Alto Neuroscience, Inc. board of directors since October 2023. From August 2005 to December 2022, Mr. Dreyfus served in roles of increasing responsibility at Blue Cross Blue Shield of Massachusetts, a health insurance company, most recently serving as President and Chief Executive Officer from September 2010 to December 2022. Mr. Dreyfus has served as a member of the board of directors of Ironwood Pharmaceutics, Inc., a pharmaceutical company, since April 2016, and serves on numerous boards and advisory boards for non-profit organizations. Mr. Dreyfus received a B.A. in English from Connecticut College.
- Andrew Miller
-
Andrew Miller自2018年8月起担任我们的首席运营官，并于2012年4月至2019年3月担任我们的董事会成员。Miller博士是我们的创始人，在担任我们的首席运营官之前，他于2016年7月至2018年8月担任我们的总裁兼首席执行官。从2008年8月到2016年7月，米勒博士曾在PureTech Health plc担任多个职位，最后担任Vice President，PureTech Health plc的风险合伙人，并担任TAL Medical的首席运营官和Entrega，Inc.的代理首席运营官。他目前是Entrega，Inc.的董事会成员。Miller博士以最高荣誉在伊利诺伊大学（University of Illinois）获得化学工程学士学位，并在麻省理工学院（Massachusetts Institute of Technology）完成化学工程博士学位。
Andrew Miller has served as a member of Kyverna Therapeutics, Inc.'s Board since February 2026. Dr. Miller previously founded Karuna Therapeutics, Inc. ("Karuna"), a biopharmaceutical company developing treatments for psychiatric and neurological conditions. He most recently served as President of Research and Development at Karuna until its $14 billion acquisition by Bristol Myers Squibb in 2024 and previously served as Chief Operating Officer, Chief Executive Officer and as a member of Karuna's Board of Directors. Prior to that, Dr. Miller held senior and executive level positions at PureTech Health plc, Tal Medical and Entrega, Inc. He also served as a member of the board of directors of Entrega, Inc. from 2013 to 2025. Dr. Miller currently serves as the Chairman of the Board at Progentos Therapeutics. He received a B.S. in Chemical Engineering from the University of Illinois with highest honors and completed his Ph.D. in Chemical Engineering at the Massachusetts Institute of Technology. - Andrew Miller自2018年8月起担任我们的首席运营官，并于2012年4月至2019年3月担任我们的董事会成员。Miller博士是我们的创始人，在担任我们的首席运营官之前，他于2016年7月至2018年8月担任我们的总裁兼首席执行官。从2008年8月到2016年7月，米勒博士曾在PureTech Health plc担任多个职位，最后担任Vice President，PureTech Health plc的风险合伙人，并担任TAL Medical的首席运营官和Entrega，Inc.的代理首席运营官。他目前是Entrega，Inc.的董事会成员。Miller博士以最高荣誉在伊利诺伊大学（University of Illinois）获得化学工程学士学位，并在麻省理工学院（Massachusetts Institute of Technology）完成化学工程博士学位。
- Andrew Miller has served as a member of Kyverna Therapeutics, Inc.'s Board since February 2026. Dr. Miller previously founded Karuna Therapeutics, Inc. ("Karuna"), a biopharmaceutical company developing treatments for psychiatric and neurological conditions. He most recently served as President of Research and Development at Karuna until its $14 billion acquisition by Bristol Myers Squibb in 2024 and previously served as Chief Operating Officer, Chief Executive Officer and as a member of Karuna's Board of Directors. Prior to that, Dr. Miller held senior and executive level positions at PureTech Health plc, Tal Medical and Entrega, Inc. He also served as a member of the board of directors of Entrega, Inc. from 2013 to 2025. Dr. Miller currently serves as the Chairman of the Board at Progentos Therapeutics. He received a B.S. in Chemical Engineering from the University of Illinois with highest honors and completed his Ph.D. in Chemical Engineering at the Massachusetts Institute of Technology.
- Christopher Nixon Cox
-
Christopher Nixon Cox，自2022年4月起担任Alto Neuroscience，Inc.董事会成员。自2021年12月以来，考克斯先生一直担任私募股权公司Lightswitch Capital的首席执行官。此外，考克斯先生自2022年11月起担任碳抵消开发商Argali Carbon Corporation的首席执行官，自2023年10月起担任BioSource Feed Corporation的首席执行官。从2018年12月到2020年3月，考克斯先生担任上市资产管理公司Brightsphere，Inc的副董事长。Cox先生还自2006年10月起担任金融服务公司OC 伙伴全球 LLC的管理合伙人和联合创始人。此前，考克斯曾于2004年至2006年在Weil，Gotshal & Manges LLP律师事务所担任企业合伙人。考克斯先生获得了纽约大学法学院的法学博士学位、纽约大学斯特恩学院的金融学证书和普林斯顿大学的政治学学士学位。
Christopher Nixon Cox,has served as a member of Alto Neuroscience, Inc. board of directors since April 2022. Since December 2021, Mr. Cox has served as Chief Executive Officer of Lightswitch Capital, a private equity firm. In addition, Mr. Cox has served as Chief Executive Officer of Argali Carbon Corporation, a carbon offset developer, since November 2022 and of BioSource Feed Corporation since October 2023. From December 2018 until March 2020, Mr. Cox served as Vice Chairman of Brightsphere, Inc, a publicly traded asset manager. Mr. Cox has also served as the Managing Partner and co-founder of OC Global Partners LLC, a financial services company, since October 2006. Previously, Mr. Cox served as a corporate associate at the law firm of Weil, Gotshal & Manges LLP from 2004 to 2006. Mr. Cox received a J.D. from the New York University School of Law, a certificate in Finance from New York University Stern School and a B.A. in Politics from Princeton University. - Christopher Nixon Cox，自2022年4月起担任Alto Neuroscience，Inc.董事会成员。自2021年12月以来，考克斯先生一直担任私募股权公司Lightswitch Capital的首席执行官。此外，考克斯先生自2022年11月起担任碳抵消开发商Argali Carbon Corporation的首席执行官，自2023年10月起担任BioSource Feed Corporation的首席执行官。从2018年12月到2020年3月，考克斯先生担任上市资产管理公司Brightsphere，Inc的副董事长。Cox先生还自2006年10月起担任金融服务公司OC 伙伴全球 LLC的管理合伙人和联合创始人。此前，考克斯曾于2004年至2006年在Weil，Gotshal & Manges LLP律师事务所担任企业合伙人。考克斯先生获得了纽约大学法学院的法学博士学位、纽约大学斯特恩学院的金融学证书和普林斯顿大学的政治学学士学位。
- Christopher Nixon Cox,has served as a member of Alto Neuroscience, Inc. board of directors since April 2022. Since December 2021, Mr. Cox has served as Chief Executive Officer of Lightswitch Capital, a private equity firm. In addition, Mr. Cox has served as Chief Executive Officer of Argali Carbon Corporation, a carbon offset developer, since November 2022 and of BioSource Feed Corporation since October 2023. From December 2018 until March 2020, Mr. Cox served as Vice Chairman of Brightsphere, Inc, a publicly traded asset manager. Mr. Cox has also served as the Managing Partner and co-founder of OC Global Partners LLC, a financial services company, since October 2006. Previously, Mr. Cox served as a corporate associate at the law firm of Weil, Gotshal & Manges LLP from 2004 to 2006. Mr. Cox received a J.D. from the New York University School of Law, a certificate in Finance from New York University Stern School and a B.A. in Politics from Princeton University.
- Gwill York
-
Gwill York，自2021年9月起担任Alto Neuroscience，Inc.董事会成员。从1994年到2017年，约克女士担任Lighthouse Capital Partners的创始董事总经理，这是她与他人共同创立的一家风险融资公司。约克女士目前担任在布鲁塞尔泛欧交易所上市的比利时投资公司Sofina SA的董事会成员，以及多家医疗和非营利组织的董事会成员。约克女士获得了哈佛商学院的工商管理硕士学位和哈佛大学的城市与发展中经济学学士学位。
Gwill York,has served as a member of Alto Neuroscience, Inc. board of directors since September 2021. From 1994 to 2017, Ms. York served as Founding Managing Director of Lighthouse Capital Partners, a venture financing firm she co-founded. Ms. York currently serves as a member of the board of directors of Sofina SA, a Belgian investment company listed on Euronext Brussels, as well as a member of the boards of trustees of various medical and non-profit organizations. Ms. York received an M.B.A. from Harvard Business School and a B.A. in Urban and Developing Economics from Harvard University. - Gwill York，自2021年9月起担任Alto Neuroscience，Inc.董事会成员。从1994年到2017年，约克女士担任Lighthouse Capital Partners的创始董事总经理，这是她与他人共同创立的一家风险融资公司。约克女士目前担任在布鲁塞尔泛欧交易所上市的比利时投资公司Sofina SA的董事会成员，以及多家医疗和非营利组织的董事会成员。约克女士获得了哈佛商学院的工商管理硕士学位和哈佛大学的城市与发展中经济学学士学位。
- Gwill York,has served as a member of Alto Neuroscience, Inc. board of directors since September 2021. From 1994 to 2017, Ms. York served as Founding Managing Director of Lighthouse Capital Partners, a venture financing firm she co-founded. Ms. York currently serves as a member of the board of directors of Sofina SA, a Belgian investment company listed on Euronext Brussels, as well as a member of the boards of trustees of various medical and non-profit organizations. Ms. York received an M.B.A. from Harvard Business School and a B.A. in Urban and Developing Economics from Harvard University.
- Amit Etkin
-
Amit Etkin是Alto Neuroscience，Inc.的创始人，自2019年3月起担任Alto Neuroscience，Inc.首席执行官和Alto Neuroscience，Inc.董事会主席，自2023年11月起担任Alto Neuroscience，Inc.总裁。在组建Alto之前，Etkin博士曾在斯坦福大学医学院担任精神病学和行为科学教授，自2010年7月以来，他在该学院担任多个领导职务。作为终身教授，埃特金博士成为精神疾病及其治疗神经科学领域的国际领导者。Etkin博士在斯坦福大学完成了精神病学培训，并在哥伦比亚大学获得神经生物学医学博士和博士学位，在哥伦比亚大学获得神经生物学硕士学位，在麻省理工学院获得生物学学士学位。
Amit Etkin,is Alto Neuroscience, Inc. Founder and has served as Alto Neuroscience, Inc. Chief Executive Officer and the Chair of Alto Neuroscience, Inc. board of directors since March 2019 and as Alto Neuroscience, Inc. President since November 2023. Prior to forming Alto, Dr. Etkin served as a Professor of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine, where he was on staff in multiple leading roles since July 2010. As a tenured Professor, Dr. Etkin became an international leader in the neuroscience of psychiatric disorders and their treatments. Dr. Etkin completed his psychiatry training at Stanford University and received an M.D. and a Ph.D. in Neurobiology at Columbia University, an M.Phil. in Neurobiology from Columbia University, and a B.S. in Biology from the Massachusetts Institute of Technology. - Amit Etkin是Alto Neuroscience，Inc.的创始人，自2019年3月起担任Alto Neuroscience，Inc.首席执行官和Alto Neuroscience，Inc.董事会主席，自2023年11月起担任Alto Neuroscience，Inc.总裁。在组建Alto之前，Etkin博士曾在斯坦福大学医学院担任精神病学和行为科学教授，自2010年7月以来，他在该学院担任多个领导职务。作为终身教授，埃特金博士成为精神疾病及其治疗神经科学领域的国际领导者。Etkin博士在斯坦福大学完成了精神病学培训，并在哥伦比亚大学获得神经生物学医学博士和博士学位，在哥伦比亚大学获得神经生物学硕士学位，在麻省理工学院获得生物学学士学位。
- Amit Etkin,is Alto Neuroscience, Inc. Founder and has served as Alto Neuroscience, Inc. Chief Executive Officer and the Chair of Alto Neuroscience, Inc. board of directors since March 2019 and as Alto Neuroscience, Inc. President since November 2023. Prior to forming Alto, Dr. Etkin served as a Professor of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine, where he was on staff in multiple leading roles since July 2010. As a tenured Professor, Dr. Etkin became an international leader in the neuroscience of psychiatric disorders and their treatments. Dr. Etkin completed his psychiatry training at Stanford University and received an M.D. and a Ph.D. in Neurobiology at Columbia University, an M.Phil. in Neurobiology from Columbia University, and a B.S. in Biology from the Massachusetts Institute of Technology.
- Husseini Manji
-
Husseini Manji，被任命为Alto Neuroscience，Inc.董事会成员，在紧接执行与本次发行相关的承销协议之前生效。自2023年5月起，Manji博士担任英国政府心理健康使命的联合主席。Manji博士自2021年6月起担任牛津大学教授，自2006年7月起担任杜克大学医学院客座教授。Manji博士此前曾于2020年7月至2022年7月在制药公司强生担任思维科学全球主管。Manji博士于2008年6月至2020年7月在制药公司强生的杨森制药公司担任神经科学全球治疗主管。Manji博士获得了不列颠哥伦比亚大学的医学博士学位和不列颠哥伦比亚大学的生物化学学士学位。Manji博士从加拿大皇家内科医生和外科医生学院获得加拿大皇家内科医生学院院士称号。Alto Neuroscience，Inc.董事会认为，Manji博士在神经科学领域的专业知识和经验使他有资格担任Alto Neuroscience，Inc.董事会成员。
Husseini Manji,was appointed as a member of Alto Neuroscience, Inc. board of directors effective immediately prior to the execution of the underwriting agreement related to this offering. Since May 2023, Dr. Manji has served as Co-Chair of the U.K. Government Mental Health Mission. Dr. Manji has served as a professor at the University of Oxford since June 2021 and has served as a visiting professor at Duke University School of Medicine since July 2006. Dr. Manji previously served as Global Head, Science for Minds at Johnson & Johnson, a pharmaceutical company, from July 2020 to July 2022. Dr. Manji served as Global Therapeutic Head, Neuroscience at the Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company, from June 2008 to July 2020. Dr. Manji received an M.D. from the University of British Columbia and a B.S. in Biochemistry from the University of British Columbia. Dr. Manji received the designation of Fellow of the Royal College of Physicians of Canada from the Royal College of Physicians and Surgeons of Canada. - Husseini Manji，被任命为Alto Neuroscience，Inc.董事会成员，在紧接执行与本次发行相关的承销协议之前生效。自2023年5月起，Manji博士担任英国政府心理健康使命的联合主席。Manji博士自2021年6月起担任牛津大学教授，自2006年7月起担任杜克大学医学院客座教授。Manji博士此前曾于2020年7月至2022年7月在制药公司强生担任思维科学全球主管。Manji博士于2008年6月至2020年7月在制药公司强生的杨森制药公司担任神经科学全球治疗主管。Manji博士获得了不列颠哥伦比亚大学的医学博士学位和不列颠哥伦比亚大学的生物化学学士学位。Manji博士从加拿大皇家内科医生和外科医生学院获得加拿大皇家内科医生学院院士称号。Alto Neuroscience，Inc.董事会认为，Manji博士在神经科学领域的专业知识和经验使他有资格担任Alto Neuroscience，Inc.董事会成员。
- Husseini Manji,was appointed as a member of Alto Neuroscience, Inc. board of directors effective immediately prior to the execution of the underwriting agreement related to this offering. Since May 2023, Dr. Manji has served as Co-Chair of the U.K. Government Mental Health Mission. Dr. Manji has served as a professor at the University of Oxford since June 2021 and has served as a visiting professor at Duke University School of Medicine since July 2006. Dr. Manji previously served as Global Head, Science for Minds at Johnson & Johnson, a pharmaceutical company, from July 2020 to July 2022. Dr. Manji served as Global Therapeutic Head, Neuroscience at the Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company, from June 2008 to July 2020. Dr. Manji received an M.D. from the University of British Columbia and a B.S. in Biochemistry from the University of British Columbia. Dr. Manji received the designation of Fellow of the Royal College of Physicians of Canada from the Royal College of Physicians and Surgeons of Canada.
- Raymond Sanchez
-
Raymond Sanchez，在生命科学行业拥有超过20年的经验，自2024年9月起担任全球投资公司贝恩资本生命科学的高级顾问。此前，他曾于2019年1月至2024年8月被艾伯维（AbbVie Inc）收购期间，在生物制药公司Cerevel Therapeutics Holdings, Inc.（前身为纳斯达克：CERE）担任首席医疗官。2007年11月至2019年1月，Sanchez博士在Otsuka Pharmaceutical Development & Commercialization，Inc.（一家私营的医疗保健公司）担任各种职务，职责不断增加，最近一次是从2013年11月开始担任全球临床开发高级副总裁。2018年6月至2019年1月，Sanchez博士兼任制药公司Avanir Pharmaceuticals, Inc.（后被Otsuka America Pharmaceutical，Inc.收购）的首席医疗官。Sanchez博士自2024年11月起担任Rapport Therapeutics，Inc.（纳斯达克：RAPP）的董事会成员。他还担任多家私营生物技术公司的董事会成员。在加入生命科学行业之前，桑切斯博士在耶鲁大学医学院接受了精神病学培训，在那里他担任了首席住院医师以及研究员和讲师。Sanchez博士在2017年11月至2022年1月期间担任国际中枢神经系统药物开发学会的执行联合主席，还为其他学术和慈善组织如康涅狄格州心理健康中心基金会和耶鲁大学医学院做出了贡献。Sanchez博士拥有西北大学的两个学位、温伯格艺术与科学学院的心理学文学学士学位和范伯格医学院的医学学位。董事会认为，Sanchez博士在生物技术和制药行业监督医疗战略方面的丰富经验以及他在医学方面的背景使他有资格担任Alto Neuroscience，Inc.董事会成员。
Raymond Sanchez,has over 20 years of experience in the life sciences industry, and has served as a Senior Advisor at Bain Capital Life Sciences, a global investment firm, since September 2024. He previously served as Chief Medical Officer of Cerevel Therapeutics Holdings, Inc. (previously Nasdaq: CERE), a biopharmaceutical company, from January 2019 to August 2024 when it was acquired by AbbVie Inc. From November 2007 to January 2019, Dr. Sanchez held various roles of increasing responsibility at Otsuka Pharmaceutical Development&Commercialization, Inc., a privately-held healthcare company, most recently as Senior Vice President, Global Clinical Development beginning in November 2013. From June 2018 to January 2019, Dr. Sanchez concurrently served as Chief Medical Officer of Avanir Pharmaceuticals, Inc., a pharmaceutical company (later acquired by Otsuka America Pharmaceutical, Inc.). Dr. Sanchez has served as a member of the board of directors of Rapport Therapeutics, Inc. (Nasdaq: RAPP) since November 2024. He also serves on the board of directors of numerous privately held biotechnology companies. Prior to joining the life sciences industry, Dr. Sanchez trained in psychiatry at the Yale School of Medicine where he where he was Chief Resident as well as a fellow and an instructor. Dr. Sanchez was an executive co-chair of the International Society for CNS Drug Development from November 2017 to January 2022, and has also contributed to other academic and charitable organizations such as the Connecticut Mental Health Center Foundation and Yale School of Medicine. Dr. Sanchez holds two degrees from Northwestern University, a Bachelor of Arts degree in psychology from the Weinberg College of Arts and Sciences and a medical degree from the Feinberg School of Medicine. - Raymond Sanchez，在生命科学行业拥有超过20年的经验，自2024年9月起担任全球投资公司贝恩资本生命科学的高级顾问。此前，他曾于2019年1月至2024年8月被艾伯维（AbbVie Inc）收购期间，在生物制药公司Cerevel Therapeutics Holdings, Inc.（前身为纳斯达克：CERE）担任首席医疗官。2007年11月至2019年1月，Sanchez博士在Otsuka Pharmaceutical Development & Commercialization，Inc.（一家私营的医疗保健公司）担任各种职务，职责不断增加，最近一次是从2013年11月开始担任全球临床开发高级副总裁。2018年6月至2019年1月，Sanchez博士兼任制药公司Avanir Pharmaceuticals, Inc.（后被Otsuka America Pharmaceutical，Inc.收购）的首席医疗官。Sanchez博士自2024年11月起担任Rapport Therapeutics，Inc.（纳斯达克：RAPP）的董事会成员。他还担任多家私营生物技术公司的董事会成员。在加入生命科学行业之前，桑切斯博士在耶鲁大学医学院接受了精神病学培训，在那里他担任了首席住院医师以及研究员和讲师。Sanchez博士在2017年11月至2022年1月期间担任国际中枢神经系统药物开发学会的执行联合主席，还为其他学术和慈善组织如康涅狄格州心理健康中心基金会和耶鲁大学医学院做出了贡献。Sanchez博士拥有西北大学的两个学位、温伯格艺术与科学学院的心理学文学学士学位和范伯格医学院的医学学位。董事会认为，Sanchez博士在生物技术和制药行业监督医疗战略方面的丰富经验以及他在医学方面的背景使他有资格担任Alto Neuroscience，Inc.董事会成员。
- Raymond Sanchez,has over 20 years of experience in the life sciences industry, and has served as a Senior Advisor at Bain Capital Life Sciences, a global investment firm, since September 2024. He previously served as Chief Medical Officer of Cerevel Therapeutics Holdings, Inc. (previously Nasdaq: CERE), a biopharmaceutical company, from January 2019 to August 2024 when it was acquired by AbbVie Inc. From November 2007 to January 2019, Dr. Sanchez held various roles of increasing responsibility at Otsuka Pharmaceutical Development&Commercialization, Inc., a privately-held healthcare company, most recently as Senior Vice President, Global Clinical Development beginning in November 2013. From June 2018 to January 2019, Dr. Sanchez concurrently served as Chief Medical Officer of Avanir Pharmaceuticals, Inc., a pharmaceutical company (later acquired by Otsuka America Pharmaceutical, Inc.). Dr. Sanchez has served as a member of the board of directors of Rapport Therapeutics, Inc. (Nasdaq: RAPP) since November 2024. He also serves on the board of directors of numerous privately held biotechnology companies. Prior to joining the life sciences industry, Dr. Sanchez trained in psychiatry at the Yale School of Medicine where he where he was Chief Resident as well as a fellow and an instructor. Dr. Sanchez was an executive co-chair of the International Society for CNS Drug Development from November 2017 to January 2022, and has also contributed to other academic and charitable organizations such as the Connecticut Mental Health Center Foundation and Yale School of Medicine. Dr. Sanchez holds two degrees from Northwestern University, a Bachelor of Arts degree in psychology from the Weinberg College of Arts and Sciences and a medical degree from the Feinberg School of Medicine.
高管简历
中英对照 | 中文 | 英文- Amit Etkin
Amit Etkin是Alto Neuroscience，Inc.的创始人，自2019年3月起担任Alto Neuroscience，Inc.首席执行官和Alto Neuroscience，Inc.董事会主席，自2023年11月起担任Alto Neuroscience，Inc.总裁。在组建Alto之前，Etkin博士曾在斯坦福大学医学院担任精神病学和行为科学教授，自2010年7月以来，他在该学院担任多个领导职务。作为终身教授，埃特金博士成为精神疾病及其治疗神经科学领域的国际领导者。Etkin博士在斯坦福大学完成了精神病学培训，并在哥伦比亚大学获得神经生物学医学博士和博士学位，在哥伦比亚大学获得神经生物学硕士学位，在麻省理工学院获得生物学学士学位。
Amit Etkin,is Alto Neuroscience, Inc. Founder and has served as Alto Neuroscience, Inc. Chief Executive Officer and the Chair of Alto Neuroscience, Inc. board of directors since March 2019 and as Alto Neuroscience, Inc. President since November 2023. Prior to forming Alto, Dr. Etkin served as a Professor of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine, where he was on staff in multiple leading roles since July 2010. As a tenured Professor, Dr. Etkin became an international leader in the neuroscience of psychiatric disorders and their treatments. Dr. Etkin completed his psychiatry training at Stanford University and received an M.D. and a Ph.D. in Neurobiology at Columbia University, an M.Phil. in Neurobiology from Columbia University, and a B.S. in Biology from the Massachusetts Institute of Technology.- Amit Etkin是Alto Neuroscience，Inc.的创始人，自2019年3月起担任Alto Neuroscience，Inc.首席执行官和Alto Neuroscience，Inc.董事会主席，自2023年11月起担任Alto Neuroscience，Inc.总裁。在组建Alto之前，Etkin博士曾在斯坦福大学医学院担任精神病学和行为科学教授，自2010年7月以来，他在该学院担任多个领导职务。作为终身教授，埃特金博士成为精神疾病及其治疗神经科学领域的国际领导者。Etkin博士在斯坦福大学完成了精神病学培训，并在哥伦比亚大学获得神经生物学医学博士和博士学位，在哥伦比亚大学获得神经生物学硕士学位，在麻省理工学院获得生物学学士学位。
- Amit Etkin,is Alto Neuroscience, Inc. Founder and has served as Alto Neuroscience, Inc. Chief Executive Officer and the Chair of Alto Neuroscience, Inc. board of directors since March 2019 and as Alto Neuroscience, Inc. President since November 2023. Prior to forming Alto, Dr. Etkin served as a Professor of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine, where he was on staff in multiple leading roles since July 2010. As a tenured Professor, Dr. Etkin became an international leader in the neuroscience of psychiatric disorders and their treatments. Dr. Etkin completed his psychiatry training at Stanford University and received an M.D. and a Ph.D. in Neurobiology at Columbia University, an M.Phil. in Neurobiology from Columbia University, and a B.S. in Biology from the Massachusetts Institute of Technology.
- Nicholas Smith
Nicholas Smith，自2022年11月起担任Alto Neuroscience，Inc. 首席财务官，自2021年9月起担任Alto Neuroscience，Inc.首席商务官。史密斯先生还在2023年7月至2023年10月期间担任Alto Neuroscience，Inc.董事会成员。在加入Alto Neuroscience，Inc.之前，Smith先生曾于2017年3月至2021年9月在专注于CNS的生物制药公司Aptinyx Inc.担任多个职务，包括2021年3月至2021年9月担任投资者关系和企业发展副总裁，2019年3月至2021年3月担任企业发展和投资者关系高级总监，2017年3月至2019年3月担任企业发展总监。史密斯先生在北方中央学院获得会计和金融学士学位。
Nicholas Smith,has served as Alto Neuroscience, Inc. Chief Financial Officer since November 2022 and has served as Alto Neuroscience, Inc. Chief Business Officer since September 2021. Mr. Smith also served as a member of Alto Neuroscience, Inc. board of directors from July 2023 through October 2023. Prior to joining Alto Neuroscience, Inc. , Mr. Smith served in various roles at Aptinyx Inc., a CNS-focused biopharmaceutical company, from March 2017 until September 2021, including Vice President, Investor Relations and Corporate Development from March 2021 to September 2021, Senior Director, Corporate Development and Investor Relations from March 2019 to March 2021, and Director, Corporate Development from March 2017 to March 2019. Mr. Smith received a B.A. in Accounting and Finance from North Central College.- Nicholas Smith，自2022年11月起担任Alto Neuroscience，Inc. 首席财务官，自2021年9月起担任Alto Neuroscience，Inc.首席商务官。史密斯先生还在2023年7月至2023年10月期间担任Alto Neuroscience，Inc.董事会成员。在加入Alto Neuroscience，Inc.之前，Smith先生曾于2017年3月至2021年9月在专注于CNS的生物制药公司Aptinyx Inc.担任多个职务，包括2021年3月至2021年9月担任投资者关系和企业发展副总裁，2019年3月至2021年3月担任企业发展和投资者关系高级总监，2017年3月至2019年3月担任企业发展总监。史密斯先生在北方中央学院获得会计和金融学士学位。
- Nicholas Smith,has served as Alto Neuroscience, Inc. Chief Financial Officer since November 2022 and has served as Alto Neuroscience, Inc. Chief Business Officer since September 2021. Mr. Smith also served as a member of Alto Neuroscience, Inc. board of directors from July 2023 through October 2023. Prior to joining Alto Neuroscience, Inc. , Mr. Smith served in various roles at Aptinyx Inc., a CNS-focused biopharmaceutical company, from March 2017 until September 2021, including Vice President, Investor Relations and Corporate Development from March 2021 to September 2021, Senior Director, Corporate Development and Investor Relations from March 2019 to March 2021, and Director, Corporate Development from March 2017 to March 2019. Mr. Smith received a B.A. in Accounting and Finance from North Central College.